(Reuters) – Johnson & Johnson’s blockbuster psoriasis drug Stelara led to a significant reduction in disease activity in patients with systemic lupus compared with a placebo in a midstage clinical trial, according to data released on Saturday.

https://www.reuters.com/article/us-johnson-johnson-lupus/jjs-stelara-shows-promise-against-lupus-in-study-idUSKBN1D40WZ